ZX-29

Overview

ZX-29 is a potent and selective ALK inhibitor with an IC 50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK , ALK L1196M and ALK G1202R mutations, respectively. ZX-29 is inactive against EGFR . ZX-29 induces apoptosis by inducing endoplasmic reticulum (ER) stress and overcomes cell resistance caused by an ALK mutation. ZX-29 also induces protective autophagy and has antitumor effect.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK) | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-135887
• CAS No.: 2254805-62-2
• Molecular Formula: C23H28ClN7O3S
• Molecular Weight: 518.03
• Purity: 98.59%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.5 mg/mL (4.83 mM); Clear solution
• Availability: In-stock

Source

Original product source